RRM2B

Across TCGA pan-cancer cohorts, RRM2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RRM2B data layer compared with 18 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RRM2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RRM2B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where RRM2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.718	1.000	.010	25	view →
HNSC	OS	Quartile	III,IV	0.658	0.906	.013	4	view →
LSCC	DFS	Median	III,IV	0.988	0.575	.015	3	view →
LUAD	OS	Tertile	III,IV	0.701	0.366	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RRM2B–CCRCC (OS)

Open the CCRCC breakdown →